title: Increased risk of hemorrhagic complications in renal allograft recipients receiving systemic heparin early posttransplantation.
abstract: The aim of this paper is to document the risk of hemorrhagic complications in renal allograft recipients requiring systemic heparinisation within the first 2 weeks posttransplantation.
  
  
  METHODS
  A retrospective chart review of 326 RA recipients from January 1998 to July 2003 was subjected to statistics by SPIDA with P values <.05 considered significant.
  
  
  RESULTS
  16/326 (4.9%) recipients were initiated on intravenous (IV) heparin within the study period. Enoxaparin was subsequently used in 10/16 (62.5%) of these recipients. Intravenous heparin was instituted at a median 8 (1-14) days posttransplantation. Hemorrhagic complications occurred in 10/16 (62.5%) recipients on IV heparin versus 11/310 (3.5%) nonanticoagulated RA recipients (P = .0001). Hemorrhage occurred at a mean 9.75 (2-43) days into the course of IV heparin. The median peak APTT 24 hours prior to hemorrhage in RA recipients on heparin was 68.5 (58-180) versus a median peak APTT of 70 (50-140) among recipients on heparin who did not sustain a hemorrhagic complication (P = .30). A major intervention (predominantly surgery) was required in 6/16 (37%) recipients on IV heparin versus 7/310 (2.2%) nonheparinised RA recipients (P < .0001). Enoxaparin was instituted at a mean 22.5 (4-55) days posttransplantation. Delayed hemorrhage subsequently occurred in 4/10 (40%) recipients on enoxaparin. In conclusion, major and minor hemorrhagic complications occur more commonly among recipients requiring early post transplant IV heparin. Hemorrhage occurred despite APTT monitoring with APTT levels tending to be similar in RA recipients with versus without complications. Delayed hemorrhage was also seen with the subsequent use of enoxaparin.
authors.affiliation: Transplant Services, Royal Prince Alfred Hospital, Camperdown, Australia.
authors.forename: T
authors.initials: T
authors.lastname: Kusyk
authors.forename: D
authors.initials: D
authors.lastname: Verran
authors.forename: G
authors.initials: G
authors.lastname: Stewart
authors.forename: B
authors.initials: B
authors.lastname: Ryan
authors.forename: J
authors.initials: J
authors.lastname: Fisher
authors.forename: K
authors.initials: K
authors.lastname: Tsacalos
authors.forename: S
authors.initials: S
authors.lastname: Chadban
authors.forename: J
authors.initials: J
authors.lastname: Eris
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008499:Medical Records; D010314:Partial Thromboplastin Time; D011183:Postoperative Complications / Q000453:epidemiology; D011184:Postoperative Period; D012189:Retrospective Studies; D018570:Risk Assessment; D014184:Transplantation, Homologous
chemical_list: D000925:Anticoagulants; D006493:Heparin